GLAND PHARMA share price has zoomed 4% and is presently trading at Rs 2,191.4.
Meanwhile, the BSE HEALTHCARE index is at 40,404.1 (up 0.8%).
Among the top gainers in the BSE HEALTHCARE index today are ERIS LIFESCIENCES (up 3.1%) and ASTRAZENECA PHARMA (up 3.1%).
FORTIS HEALTHCARE (down 1.2%) and SUN PHARMA ADV. RES. (down 1.0%) are among the top losers today.
Over the last one year, GLAND PHARMA has moved up from Rs 1,288.2 to Rs 2,191.4, registering a gain of Rs 903.3 (up 70.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,485.7 to 40,404.1, registering a gain of 47.0% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 127.3%), GRANULES INDIA (up 102.7%) and SUVEN PHARMACEUTICALS (up 102.1%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,156.7 (up 0.5%).
The top gainers among the BSE Sensex today are Tech Mahindra (up 2.1%) and JSW Steel (up 1.8%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,155.9 (up 0.4%). Tech Mahindra and Grasim Industries are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,782.8 to 79,156.7, registering a gain of 13,373.9 points (up 20.3%).
GLAND PHARMA net profit grew 144.6% YoY to Rs 1,924 million for the quarter ended March 2024, compared to a profit of Rs 787 million a year ago. Net sales rose 95.9% to Rs 15,375 million during the period as against Rs 7,850 million in January-March 2023.
For the year ended March 2023, GLAND PHARMA reported 35.5% decrease in net profit to Rs 7,810 million compared to net profit of Rs 12,117 million during FY22. Revenue of the company fell 17.6% to Rs 36,246 million during FY23.
The current Price to earnings ratio of GLAND PHARMA, based on rolling 12 month earnings, stands at 46.7.
Equitymaster requests your view! Post a comment on "GLAND PHARMA Gains 4%; BSE HEALTHCARE Index Up 0.8%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!